Multiple Sclerosis Resource Centre
  • Home
  • About MS
  • MSRC Services
  • Get Involved
  • MS Research News
  • MSRC Groups
  • Useful Resources
  • Welcome To Josephs Court, MS Centre Of Excellence
  • Advertising
  • Best Bet Diet Group
  • E-Newsletter
  • Contact Us
  • Investor in People
    You are here : Home » MS Research News » CRMP-2

    CRMP-2

    A A A
    [Print this page]

    Share |


    More news can be found in New Pathways Magazine, our bi-monthly publication, and also check daily at MSRC: Latest MS News.

    Protein block `could halt multiple sclerosis`
    MS MRI Scientists claim to have discovered that the progress of debilitating disease multiple sclerosis could be slowed or even stopped by blocking a protein which contributes to nerve damage.

    An international team has shown that the key role played by the collapsing response mediator protein 2 (CRMP-2)) in the development of multiple sclerosis (MS), the `Brain` journal reported.

    In their research, the scientists found that a modified version of CRMP-2 is present in active MS lesions, which indicate damage to the nervous system, in a laboratory model of MS.

    The modified CRMP-2 interacts with another protein to cause nerve fibre damage that can result in numbness, blindness, difficulties with speech and motor skills, and cognitive impairments in sufferers.

    When either the modified CRMP-2 or the interaction between the two proteins was blocked, using a method already approved in both the US and Australia, the progression of the disease was halted.

    The scientists say that the discovery could lead to new treatments for MS.

    "Blocking the same protein in people with MS could provide a `handbrake` to the progression of the disease," Prof Richard Boyd of Monash University, a team member, said.

    Dr Steven Petratos, the team leader, said the method used to block the protein was approved for the treatment of other disease conditions by both the US Food and Drug Administration and Australia's Therapeutic Goods Administration.

    "This should mean that clinical trials -- once they start -- will be fast tracked as the form of administration has already been approved," he added.

    Source: ZeeNews.com © 1998-2012 Zee News Limited (30/04/12)

    © Multiple Sclerosis Resource Centre

    Related Items
    Bacteria
    Biomarkers And MicroRNA
    Blood Tests And MS
    Botox
    Brain Inflammation
    Brain Iron Deposits
    Cancer And MS
    Chronic Cerebrospinal Venous Insufficiency (CCSVI)
    Cognition and Cognitive Issues
    Diet And MS
    Drugs
    Endo-parasites & 'Helpful' Organisms
    Environmental Factors And MS
    Ethnic Groups and MS
    Exercise And MS
    Genetics and MS
    Hormones And MS
    Immune Cells And MS
    Kallikrein 6
    Lightning Process® And Multiple Sclerosis
    Lipids And MS
    Lymphoid Tissue Inducer (LTi) Cells
    Medical Imaging
    MS Stem Cell Research & Treatment
    MS Symptoms
    Myelin
    Nerve And Brain Cells
    Neuropsychiatric and Psychological
    Neurosteroids
    Osteoporosis And MS
    Paediatric MS
    Pain
    Potential Viral Causes Of MS
    Pregnancy And MS
    Quality Of Life
    Stress And MS
    Technology And MS
    The Blood Brain Barrier
    Types Of MS
    Vaccinations & MS
    Vitamin D


    Did you find this information useful? Would you like to comment on this page? Let us know what you think! We welcome all comments and feedback on any aspect of our website - please click here to contact us.